Topical bevacizumab for corneal neovascularization after penetrating keratoplasty. 2009

Sandeep Saxena, and Poonam Kishore, and Sukant Pandey, and Mohit Khattri, and Dipak Kumar
Department of Ophthalmology, CSM Medical University (Erstwhile King George's Medical University), Lucknow - India. sandeepsaxena2020@yahoo.com

OBJECTIVE To evaluate the efficacy of topical bevacizumab for corneal neovascularization in graft rejection. METHODS A 55-year-old man presented with corneal neovascularization and graft rejection 6 months following penetrating keratoplasty (triple procedure) in the left eye. His best-corrected visual acuity (BCVA) was counting fingers at 1 meter. He was administered topical bevacizumab (4 mg/4 mL) in a dose of one drop twice a day for 15 days. No adjunct therapy was given during bevacizumab administration. RESULTS After 1 month, his BCVA improved to 20/120. Corneal vascularization and stromal haze regressed. After 6 months, his BCVA improved to 20/60 with further regression in corneal vascularization and stromal haze. At 9-month follow-up, he maintained BCVA of 20/60. CONCLUSIONS Short-term topical bevacizumab therapy may potentially offer a safer and more effective alternative in treating graft rejection after penetrating keratoplasty.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D006084 Graft Rejection An immune response with both cellular and humoral components, directed against an allogeneic transplant, whose tissue antigens are not compatible with those of the recipient. Transplant Rejection,Rejection, Transplant,Transplantation Rejection,Graft Rejections,Rejection, Graft,Rejection, Transplantation,Rejections, Graft,Rejections, Transplant,Rejections, Transplantation,Transplant Rejections,Transplantation Rejections
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000068258 Bevacizumab An anti-VEGF humanized murine monoclonal antibody. It inhibits VEGF RECEPTORS and helps to prevent PATHOLOGIC ANGIOGENESIS. Avastin,Bevacizumab-awwb,Mvasi,Bevacizumab awwb
D000287 Administration, Topical The application of drug preparations to the surfaces of the body, especially the skin (ADMINISTRATION, CUTANEOUS) or mucous membranes. This method of treatment is used to avoid systemic side effects when high doses are required at a localized area or as an alternative systemic administration route, to avoid hepatic processing for example. Drug Administration, Topical,Administration, Topical Drug,Topical Administration,Topical Drug Administration,Administrations, Topical,Administrations, Topical Drug,Drug Administrations, Topical,Topical Administrations,Topical Drug Administrations
D000911 Antibodies, Monoclonal Antibodies produced by a single clone of cells. Monoclonal Antibodies,Monoclonal Antibody,Antibody, Monoclonal
D014792 Visual Acuity Clarity or sharpness of OCULAR VISION or the ability of the eye to see fine details. Visual acuity depends on the functions of RETINA, neuronal transmission, and the interpretative ability of the brain. Normal visual acuity is expressed as 20/20 indicating that one can see at 20 feet what should normally be seen at that distance. Visual acuity can also be influenced by brightness, color, and contrast. Acuities, Visual,Acuity, Visual,Visual Acuities
D015948 Keratoplasty, Penetrating Partial or total replacement of all layers of a central portion of the cornea. Keratoplasties, Penetrating,Penetrating Keratoplasties,Penetrating Keratoplasty
D016510 Corneal Neovascularization New blood vessels originating from the corneal blood vessels and extending from the limbus into the adjacent CORNEAL STROMA. Neovascularization in the superficial and/or deep corneal stroma is a sequel to numerous inflammatory diseases of the ocular anterior segment, such as TRACHOMA, viral interstitial KERATITIS, microbial KERATOCONJUNCTIVITIS, and the immune response elicited by CORNEAL TRANSPLANTATION. Corneal Angiogenesis,Angiogenesis, Corneal,Corneal Neovascularizations,Neovascularization, Corneal,Neovascularizations, Corneal

Related Publications

Sandeep Saxena, and Poonam Kishore, and Sukant Pandey, and Mohit Khattri, and Dipak Kumar
November 1995, Cornea,
Sandeep Saxena, and Poonam Kishore, and Sukant Pandey, and Mohit Khattri, and Dipak Kumar
April 2009, International ophthalmology,
Sandeep Saxena, and Poonam Kishore, and Sukant Pandey, and Mohit Khattri, and Dipak Kumar
June 2007, Archives of ophthalmology (Chicago, Ill. : 1960),
Sandeep Saxena, and Poonam Kishore, and Sukant Pandey, and Mohit Khattri, and Dipak Kumar
January 2013, Pharmacology,
Sandeep Saxena, and Poonam Kishore, and Sukant Pandey, and Mohit Khattri, and Dipak Kumar
January 2020, Clinical ophthalmology (Auckland, N.Z.),
Sandeep Saxena, and Poonam Kishore, and Sukant Pandey, and Mohit Khattri, and Dipak Kumar
July 2009, Klinische Monatsblatter fur Augenheilkunde,
Sandeep Saxena, and Poonam Kishore, and Sukant Pandey, and Mohit Khattri, and Dipak Kumar
October 1986, Ophthalmology,
Sandeep Saxena, and Poonam Kishore, and Sukant Pandey, and Mohit Khattri, and Dipak Kumar
November 2013, Cornea,
Sandeep Saxena, and Poonam Kishore, and Sukant Pandey, and Mohit Khattri, and Dipak Kumar
May 2007, Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft,
Sandeep Saxena, and Poonam Kishore, and Sukant Pandey, and Mohit Khattri, and Dipak Kumar
June 2008, Ophthalmology,
Copied contents to your clipboard!